In a landmark settlement with the US Justice Department, Chinese e-commerce conglomerate Alibaba and its US-based payment processor AUS Merchant Services have agreed to pay $600 million to address allegations of failing to prevent illegal drug sales on their platforms. The agreement, which includes admissions of culpability and enhanced compliance measures, was reached after an investigation spanning from 2016 to 2024 that uncovered around 80,000 instances of illicit chemical, drug, and pharmaceutical counterfeiting equipment sales. These transactions, totaling over $200 million in merchandise value, were imported from overseas through Alibaba's e-commerce platforms, according to the Justice Department. During this period, law enforcement conducted over 40 undercover purchases of illegal pharmaceuticals and counterfeiting equipment, highlighting inadequacies in Alibaba's compliance measures. On occasion, Alibaba employees expressed concerns about the sale of illicit products but did not implement sufficient controls to prevent these sales. In addition to Alibaba, the US government found that the US-based payment processor's anti-money laundering compliance program had failed to prevent certain merchants from using its services to facilitate the importation of banned products into the United States. Assistant US Attorney General Brett Shumate commented on the settlement, stating, "Today's resolution reflects the Department of Justice's commitment to ensuring that companies operating e-commerce and digital payment platforms keep illegal, unapproved, misbranded, and dangerous foreign pharmaceuticals off their marketplaces." Alibaba, which operates some of the world's largest e-commerce platforms such as Alibaba.com and AliExpress.com, has pledged to uphold best-in-class standards of control, policies, and measures against non-compliant product sales in the wake of this settlement.